Iran pituitary tumor registry: Description of the program and initial results

Khamseh, M.E. and Mohajeri Tehrani, M.R. and Mousavi, Z. and Malek, M. and Imani, M. and Tehrani, N.H. and Ghorbani, M. and Akbari, H. and Sarvghadi, F. and Amouzegar, A. and Esfahanian, F. and Madani, N.H. and Emami, Z. (2017) Iran pituitary tumor registry: Description of the program and initial results. Archives of Iranian Medicine, 20 (12). pp. 746-751.

Full text not available from this repository.
Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....

Abstract

Background: This study was designed to present initial results on clinical presentation, therapeutic modalities, and outcome information of patients with pituitary tumors registered in Iran Pituitary Tumor Registry (IPTR). Methods: We collected data from a web-based electronic medical records of patients with various pituitary tumors referred to four tertiary care centers in the country. Retrospective analysis was performed on demographic, clinical, and therapeutic information of 298 patients including 51 clinically nonfunctioning adenoma (CNFA), 85 acromegaly, 135 prolactinoma, and 27 Cushing�s disease (CD). Results: From October 2014 to July 2016, 298 people with the diagnosis of pituitary tumor were registered. Prolactinoma was the most prevalent tumor (45.3), followed by Acromegaly (28.6), CNFPA (17.1), and CD (9). Female dominance was seen among patients with prolactinoma and CD, while the majority of patients with CNFPA were male and acromegaly was equally distributed between men and women. Hypogonadal symptoms were almost always seen in all types of pituitary groups. Surgery alone was the most common therapeutic modality used in cases of acromegaly, CNFPA, and CD. However, medical therapy alone was frequently applied for cases of prolactinoma. Finally, biochemical cure was achieved in most cases of prolactinoma and CD, but only in 36.5 of acromegalics. Moreover, 80 of patients suffering from CNFPA showed no residual tumor in their imaging. Conclusion: In conclusion, this comprehensive tumor registry enables early identification, selection of best therapeutic approaches, and evaluation of long-term treatment outcomes. Furthermore, this registry can be used to improve surveillance protocols. © 2017 The Author(s).

Item Type: Article
Additional Information: cited By 0
Uncontrolled Keywords: corticotropin; dexamethasone; growth hormone; prolactin, acromegaly; adenoma; adult; arthralgia; Article; body mass; cancer registry; Cushing disease; diabetes insipidus; fatigue; female; galactorrhea; headache; human; hypophysis adenoma; hypophysis tumor; hypopituitarism; imaging; immunohistochemistry; major clinical study; male; nuclear magnetic resonance imaging; prolactinoma; tumor regression; tumor volume; visual field defect
Subjects: WF Respiratory System
Depositing User: eprints admin
Date Deposited: 30 Dec 2018 09:55
Last Modified: 30 Dec 2018 09:55
URI: http://eprints.iums.ac.ir/id/eprint/7552

Actions (login required)

View Item View Item